Innovent Announces the NMPA Granted Marketing Approval for BYVASDA (Bevacizumab Biosimilar) in China

Innovent Biologics, Inc., a biopharmaceutical company that develops, manufactures and commercializes medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that BYVASDA (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug independently developed by Innovent, has been officially approved by the National Medical Products Administration (NMPA) of China for patients with advanced non-small cell lung cancer and metastatic colorectal cancer in China.

BYVASDA is Innovent's second monoclonal antibody drug approved by the NMPA following TYVYT (sintilimab injection, officially approved for treatment of patients with Hodgkin's lymphoma in December 2018).

 BYVASDA is an anti-VEGF humanized monoclonal antibody and a bevacizumab biosimilar independently developed by Innovent. The launch of BYVASDA will provide Chinese patients with high-quality and relatively more affordable bevacizumab biosimilar injection.

Dr. Hui Zhou, Vice President and Head of Oncology Strategy and Medical Sciences of Innovent, stated: "BYVASDA is another example of our success with the National Major New Drug Innovation and Development Projects and the second monoclonal antibody drug approved by the NMPA following TYVYT® (sintilimab injection). We hope to bring this high-quality and cost-saving drugs to more patients in need in China as soon as possible. In January 2020, Innovent out-licensed the commercial rights of BYVASDA in the United States and Canada to Coherus BioSciences, a leading biosimilar company, demonstrated an international recognition of the quality of BYVASDA. We are looking forward to working together to make BYVASDA benefit more patients globally."